Glaxosmithkline | Les Charges D'Exploitation



Operating Expenses Changement Date
AbbVie USD 16.59B 5.96B 2024-12
Amgen USD 6.78B 401M 2024-12
AstraZeneca USD 12.86B 2.06B 2024-12
Aurora Cannabis CAD 51.98M 31.53M 2024-12
Bausch Health Companies USD 2.19B 212M 2024-09
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Canopy Growth CAD 98.58M 10.03M 2024-12
Corcept Therapeutics USD 156.63M 20.68M 2024-12
Drreddys Laboratories INR 64.87B 2.26B 2024-12
Eli Lilly USD 8.38B 1.53B 2024-12
GlaxoSmithKline GBP 7.42B 402M 2024-12
Glaxosmithkline GBP 7.42B 408M 2024-12
Indivior 213M 218M 2024-09
J&J USD 18.63B 500M 2024-12
Merck USD 11.33B 1.4B 2024-12
Novartis USD 11.28B 1.73B 2024-12
Pacira USD 162.55M 145.55M 2024-12
Perrigo USD 1.03B 13.4M 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Prestige Brands USD 198.36M 1.09M 2024-12
Roche Holding CHF 11.43B 1.48B 2024-12
Sanofi EUR 10.07B 969M 2024-09
Supernus Pharmaceuticals USD 152.75M 17.91M 2024-12
Takeda JPY 1.08T 85.39B 2024-12
Teva Pharmaceutical Industries USD 3.77B 609M 2024-12
Zoetis USD 1.59B 71M 2024-12



Glaxosmithkline Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.